Potential solutions for manufacture of CAR T cells in cancer immunotherapy
CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups.
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-09-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-022-32866-0 |
| _version_ | 1798003033223725056 |
|---|---|
| author | Ulrich Blache Georg Popp Anna Dünkel Ulrike Koehl Stephan Fricke |
| author_facet | Ulrich Blache Georg Popp Anna Dünkel Ulrike Koehl Stephan Fricke |
| author_sort | Ulrich Blache |
| collection | DOAJ |
| description | CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups. |
| first_indexed | 2024-04-11T12:01:35Z |
| format | Article |
| id | doaj.art-2972014f65864c6caffed95aff62b0a0 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-11T12:01:35Z |
| publishDate | 2022-09-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-2972014f65864c6caffed95aff62b0a02022-12-22T04:24:50ZengNature PortfolioNature Communications2041-17232022-09-011311510.1038/s41467-022-32866-0Potential solutions for manufacture of CAR T cells in cancer immunotherapyUlrich Blache0Georg Popp1Anna Dünkel2Ulrike Koehl3Stephan Fricke4Fraunhofer Institute for Cell Therapy and Immunology (IZI)Fraunhofer Institute for Cell Therapy and Immunology (IZI)Fraunhofer Institute for Cell Therapy and Immunology (IZI)Fraunhofer Institute for Cell Therapy and Immunology (IZI)Fraunhofer Institute for Cell Therapy and Immunology (IZI)CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups.https://doi.org/10.1038/s41467-022-32866-0 |
| spellingShingle | Ulrich Blache Georg Popp Anna Dünkel Ulrike Koehl Stephan Fricke Potential solutions for manufacture of CAR T cells in cancer immunotherapy Nature Communications |
| title | Potential solutions for manufacture of CAR T cells in cancer immunotherapy |
| title_full | Potential solutions for manufacture of CAR T cells in cancer immunotherapy |
| title_fullStr | Potential solutions for manufacture of CAR T cells in cancer immunotherapy |
| title_full_unstemmed | Potential solutions for manufacture of CAR T cells in cancer immunotherapy |
| title_short | Potential solutions for manufacture of CAR T cells in cancer immunotherapy |
| title_sort | potential solutions for manufacture of car t cells in cancer immunotherapy |
| url | https://doi.org/10.1038/s41467-022-32866-0 |
| work_keys_str_mv | AT ulrichblache potentialsolutionsformanufactureofcartcellsincancerimmunotherapy AT georgpopp potentialsolutionsformanufactureofcartcellsincancerimmunotherapy AT annadunkel potentialsolutionsformanufactureofcartcellsincancerimmunotherapy AT ulrikekoehl potentialsolutionsformanufactureofcartcellsincancerimmunotherapy AT stephanfricke potentialsolutionsformanufactureofcartcellsincancerimmunotherapy |